HC Wainwright Issues Negative Outlook for ALGS Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Stock analysts at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Aligos Therapeutics in a research note issued on Tuesday, March 11th. HC Wainwright analyst E. Arce now expects that the company will earn ($2.37) per share for the quarter, down from their prior estimate of ($1.85). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($10.36) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q2 2025 earnings at ($2.35) EPS, Q3 2025 earnings at ($2.62) EPS, Q4 2025 earnings at $5.91 EPS, FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($8.97) EPS, FY2027 earnings at ($9.99) EPS, FY2028 earnings at ($9.24) EPS and FY2029 earnings at ($9.12) EPS.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Monday, March 10th. The company reported ($13.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.63) by ($10.45). The firm had revenue of $0.63 million during the quarter, compared to analysts’ expectations of $0.43 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same quarter last year, the company posted ($5.50) earnings per share.

Aligos Therapeutics Price Performance

Shares of ALGS stock opened at $10.28 on Thursday. The firm has a market cap of $36.88 million, a P/E ratio of -0.77 and a beta of 2.52. Aligos Therapeutics has a 1-year low of $6.76 and a 1-year high of $46.80. The firm’s 50-day simple moving average is $24.89 and its 200-day simple moving average is $20.39.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its holdings in shares of Aligos Therapeutics by 2,073.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 652 shares of the company’s stock worth $26,000 after acquiring an additional 622 shares during the period. AlphaMark Advisors LLC lifted its holdings in shares of Aligos Therapeutics by 1,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock worth $44,000 after acquiring an additional 1,000 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Aligos Therapeutics by 19.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company’s stock worth $569,000 after acquiring an additional 2,306 shares during the period. Golden State Wealth Management LLC purchased a new position in Aligos Therapeutics in the fourth quarter valued at approximately $107,000. Finally, Geode Capital Management LLC raised its holdings in Aligos Therapeutics by 13.3% in the fourth quarter. Geode Capital Management LLC now owns 27,253 shares of the company’s stock valued at $1,086,000 after buying an additional 3,197 shares during the period. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).